IMPORTANT INFORMATION

  • CFTR.info is an online educational resource on the genetics of cystic fibrosis (CF) and the role of CF transmembrane conductance regulator (CFTR) in normal human physiology as well as in CF.
  • The information contained herein is intended for healthcare professionals working within the European Union (EU).
  • The content of this website has been developed independently by a group of CF healthcare professionals and is for general information purposes only.
  • All of the information about CFTR and CFTR modulators has been obtained from referenced sources and is in the public domain.
  • This website is not intended to promote or advocate a particular course of treatment or any specific drug, whether licensed or unlicensed, nor is it intended to imply or suggest that any drug be used for any purpose other than that which for which it is licensed in the EU.

ABBREVIATED TERMS & CONDITIONS

  • While we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information and related graphics, or products and treatments, contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
  • In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from, or in connection with, the use of this website.
  • Through this website you are able to link to other websites which are not under our control. We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
  • Every effort is made to keep the website up and running smoothly. However, we take no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.

Please see the full Terms & Conditions before using this website.

 

I have read and understood the above

Drug & research development » Clinical trials » NCT01937325

Phase I Study of the Third Generation Adenovirus H5.001CBCFTR in Patients With Cystic Fibrosis

Official title:

Clinical Trials gov number: NCT01937325

Click on the tabs to move through the sequence.

Purpose: To assess the safety and feasibility of gene transfer with the third generation adenovirus H5.001CBCFTR in CF patients.

Phase: 1

Type: Interventional

Study sponsor: National Center for Research Resources (NCRR); University of Pennsylvania

Disease characteristics

  • Cystic fibrosis diagnosed as follows: Sweat sodium or chloride >60 mEq/L by pilocarpine iontophoresis or cystic fibrosis genotype Clinical manifestations Estimated 2-year survival greater than 50%, i.e.: FEV1 >30% of predicted PaO2 greater than 55 mm Hg on room air PaCO2 <50 mm Hg on room air
  • Prior/concurrent therapy– At least 2 months since systemic glucocorticoids At least 90 days since participation in investigational therapeutic study

Patient Characteristics

Pulmonary:

  • No pneumothorax within 12 months
  • No asthma or allergic bronchopulmonary aspergillosis requiring glucocorticoids within 2 months
  • No sputum pathogens unless sensitive to ≥2 antibiotics
  • No hemoptysis of >250 mL blood over 24 hours within 1 year

Other:

  • No active adenoviral infection Ad5 (or similar type) antibody seropositive
  • No other contraindication to protocol participation, e.g.: Drug abuse Alcoholism Psychiatric instability Inadequate motivation
  • Documented azoospermia (men)
  • Bilateral tubal ligation or hysterectomy (women)
  • Screening exams within 4 weeks prior to registration

Intervention
Genetic, H5.001CBCFTR

Geographical Location
No contacts or locations provided

Number of Participants
≤50 (≥18 years)

Primary Endpoint

Not provided

Secondary Endpoint

Not provided

Click on the tabs to move through the sequence.

H5.001CBCFTR, an adenovirus vector containing the cystic fibrosis transmembrane conductance regulator gene, is administered endobronchially. Cohort of 2 patients receive 1 of 6 H5.001CBCFTR concentrations. There is no intrapatient dose escalation.

Link:

http://www.ncbi.nlm.nih.gov/pubmed/10609658

Reference:

Zuckerman JB, Robinson CB, McCoy KS, Shell R, Sferra TJ, Chirmule N, Magosin SA, Propert KJ, Brown-Parr EC, Hughes JV, Tazelaar J, Baker C, Goldman MJ, Wilson JM. A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Hum Gene Ther. 1999 Dec 10;10(18):2973-85. PubMed PMID: 10609658.

View Trial Results